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AbstrACt
Objectives Current guidelines suggest limiting the use 
of vasopressors following traumatic injury; however, 
wide variations in practice exist. Although excessive 
vasoconstriction may be harmful, these agents may help 
reduce administration of potentially harmful resuscitation 
fluids. This systematic review aims to compare early 
vasopressor use to standard resuscitation in adults with 
trauma-induced shock.
Design Systematic review.
Data sources We searched MEDLINE, EMBASE,  
ClinicalTrials. gov and the Central Register of Controlled 
Trials from inception until October 2016, as well as the 
proceedings of 10 relevant international conferences from 
2005 to 2016.
Eligibility criteria for selecting studies Randomised 
controlled trials and controlled observational studies 
that compared the early vasopressor use with standard 
resuscitation in adults with acute traumatic injury.
results Of 8001 citations, we retrieved 18 full-text 
articles and included 6 studies (1 randomised controlled 
trial and 5 observational studies), including 2 published 
exclusively in abstract form. Across observational studies, 
vasopressor use was associated with increased short-term 
mortality, with unadjusted risk ratios ranging from 2.31 
to 7.39. However, the risk of bias was considered high in 
these observational studies because patients who received 
vasopressors were systematically sicker than patients 
treated without vasopressors. One clinical trial (n=78) 
was too imprecise to yield meaningful results. Two clinical 
trials are currently ongoing. No study measured long-term 
quality of life or cognitive function.
Conclusions Existing data on the effects of vasopressors 
following traumatic injury are of very low quality according 
to the Grading of Recommendations, Assessment, 
Development and Evaluation methodology. With emerging 
evidence of harm associated with aggressive fluid 
resuscitation and, in selected subgroups of patients, with 
permissive hypotension, the alternatives to vasopressor 
therapy are limited. Observational data showing that 
vasopressors are part of usual care would provide a 
strong justification for high-quality clinical trials of early 
vasopressor use during trauma resuscitation.
trial registration number CRD42016033437.
IntrODuCtIOn
rationale
Vasopressors increase arterial pressure 
primarily by inducing vasoconstriction.1 In the 
setting of hypovolaemic shock, they are some-
times used as bridge therapy until an inter-
vention targeting the source of the problem 
can be implemented.2 For example, during 
the early phase of resuscitation following 
trauma, vasopressors can maintain a minimal 
perfusion pressure without exposing patients 
to large volumes of intravenous fluid.3–7 Early 
fluid administration, be it from massive trans-
fusions or crystalloid administration, can 
lead to life-threatening complications such as 
trauma-induced coagulopathy.3 8 Permissive 
hypotension also restricts fluid use, and in 
patients with haemorrhagic shock following 
penetrating torso injuries this strategy has 
been shown to be associated with better 
survival rates compared with aggressive 
resuscitative measures.6 However, the gener-
alisability of these findings to other trauma 
populations, such as patients with traumatic 
brain injury (TBI) or following blunt trauma, 
is unclear.9 Current guidelines consider TBI 
as an absolute contraindication to permissive 
strengths and limitations of this study
 ► This is the first systematic review of early 
vasopressor use in trauma to incorporate a detailed 
search strategy, explicit inclusion and exclusion 
criteria, and duplicate screening, data extraction and 
risk of bias assessment by independent reviewers.
 ► This review uses the Grading of Recommendations, 
Assessment, Development and Evaluation approach 
to evaluate the overall quality of evidence.
 ► Conclusions are limited by the number and 
methodological quality of the available studies.
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hypotension, as this could risk jeopardising cerebral 
perfusion.10 
In spite of this potential role as fluid-sparing adjuncts,11 
vasopressors potentiate vasoconstriction and may there-
fore worsen peripheral and organ perfusion despite high 
blood pressure values.12 Nascent haemostatic clots may 
also be dislodged if normotension is rapidly achieved in 
a bleeding patient.13 Other interventions that increase 
blood pressure with limited fluid volumes, such as hyper-
tonic saline, have been found to be harmful or to provide 
no important benefit in low risk of bias randomised 
controlled trials (RCTs).14–16 Conversely, vasopressors 
may be beneficial in populations vulnerable to hypoten-
sion, such as victims of TBI in whom hypotension doubles 
mortality.9 Thus, while trauma guidelines restrict vaso-
pressor use to cases of severe hypotension refractory to 
fluid therapy,10 17 18 the balance between the benefits and 
harms of vasopressors in trauma is unknown, and clinical 
equipoise exists. Some studies report that vasopressor use 
is common in unstable patients with trauma, particularly 
in the setting of pelvic fractures19 or TBI.20 In the latter 
case, vasopressors are administered to support systemic 
haemodynamics, and more specifically to ensure adequate 
cerebral perfusion pressures and avoid secondary neuro-
logical insults.21
Over 4.8 million trauma fatalities were documented 
worldwide in 2013 alone.22 Despite this, no systematic 
review has focused specifically on the use of vasopressors 
during the early phase of trauma resuscitation.
Objective
We undertook this systematic review to answer the 
following question: ‘In patients with acute traumatic 
injury, what is the effect of vasopressor therapy on patient 
important outcomes?’ We hypothesised that, in obser-
vational studies, early vasopressor use would be associ-
ated with worse outcomes due to prognostic imbalance 
(clinicians would use vasopressors in sicker patients); in 
contrast, we hypothesised that vasopressors would not be 
associated with worse outcomes in RCTs.
This review was performed to inform a guideline 
that addressed the same topic (https://www. magicapp. 
org/ app#/ guideline/ 1273), as part of the broader 
WikiRecs project, which aims to provide rapid, evidence-
based summaries and recommendations composed as 
synopses.23 24
MEthODs
Protocol and registration
The design and reporting of this systematic review 
(PROSPERO CRD42016033437) follow the Preferred 
Reporting Items for Systematic Reviews and Meta-Anal-
yses (PRISMA) guidelines.25 A detailed protocol is 
published separately.26
Eligibility criteria
We evaluated both clinical trials and controlled observational 
studies reporting associations between early vasopressor use 
and clinical outcomes. We define early vasopressor use as 
occurring during the prehospital or emergency depart-
ment phase of care or during emergency trauma surgery. 
Studies that addressed vasopressor use exclusively during 
the postoperative phase, after arrival to the intensive care 
unit (ICU) or >24 hours from arrival to the trauma bay were 
excluded, as were studies with non-controlled designs (eg, 
case reports and case series). We included studies only if 
their population of interest consisted of adult victims of 
acute traumatic injury, either penetrating or blunt. Vaso-
pressors included epinephrine, norepinephrine, phenyl-
ephrine, dopamine, ephedrine, vasopressin and vasopressin 
analogues. We included studies in which the intervention 
included dobutamine or other primarily inotropic drugs 
only if these accounted for <10% of the study population. 
We did not exclude studies based on clinical outcomes 
reported  provided follow-up extended to at least 24 hours. 
The detailed screening flow chart is presented in online 
supplementary appendix 1.
Information sources, search strategy and study selection
With the help of a medical librarian, we developed 
electronic search strategies for the following databases: 
MEDLINE, EMBASE, the Central Register of Controlled 
Trials and  ClinicalTrials. gov. Our search spanned from 
each database’s inception until 12 October 2016. Terms 
for circulatory shock and vasopressors were combined and 
we adapted search strategies to database-specific subject 
heading and keywords (online supplementary appendix 
2). We imposed no restrictions based on language, publi-
cation status or methodological quality.
Additionally, we manually reviewed conference 
proceedings from 10 major scientific meetings in trauma 
and critical care from 2005 to 2016 to identify additional 
relevant reports (Society of Critical Care Medicine, Euro-
pean Society of Intensive Care Medicine, International 
Society of Intensive Care and Emergency Medicine, 
American Thoracic Society, American Association for the 
Surgery of Trauma, Eastern Association for the Surgery 
of Trauma, European Society for Trauma and Emergency 
Surgery, Shock Society, European Shock Society, and the 
American College of Chest Physicians). Although the 
methods of studies published exclusively as abstracts are 
more challenging to evaluate, we performed an extensive 
search of conference proceedings in order to minimise 
the risk of publication bias.27–29
Using the Covidence web platform (www. COVIDENCE. 
org), five reviewers independently screened titles and 
abstracts in duplicate. For studies that either reviewer felt 
might be eligible, two reviewers independently screened 
full text for eligibility. Disagreements were resolved by 
discussion.
Data collection process
Using prepiloted standardised forms, pairs of reviewers 
independently extracted data from each included study. 
We contacted all authors for missing data, including those 
of studies published as abstracts.
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Data items
Data items collected included individual study character-
istics and design, inclusion and exclusion criteria, differ-
ences in baseline characteristics between intervention 
groups, type, dosing and timing of vasopressors used, raw 
data for prespecified clinical outcomes, reported results 
of adjusted and unadjusted analyses, as well as associated 
measures of uncertainty, and risk of bias domains.
Quality assessment
Single study risk of bias
We judged risk of bias at the study level using a modified 
version of the Cochrane Collaboration tool for RCTs.29 
This tool addresses randomisation, allocation conceal-
ment, blinding, loss to follow-up, selective outcome 
reporting and other risks of bias. We used the ‘Clinical 
Advances through Research and Information Tech-
nology’ group tools to assess risk of bias in observational 
studies (https:// distillercer. com/ resources/).30 31 These 
tools evaluate the selection of intervention and control 
groups, the adequacy of assessment of prognostic factors, 
exposure and clinical outcomes, statistical adjustment 
and/or matching, follow-up, similarity of cointerventions 
between groups, and other risks of bias.
Overall quality of evidence
We assessed the overall certainty of absolute effect esti-
mates at the outcome level using the ‘Grading of Recom-
mendations Assessment, Development, and Evaluation’ 
(GRADE) approach.32
The GRADE system evaluates risk of bias in the body of 
evidence, consistency of results across studies, precision 
of effect estimates and publication bias. Indirectness of 
evidence is also considered, that is, whether or not the 
population, interventions and outcomes of individual 
studies correspond to those of interest for our review. 
Taking these domains into account, GRADE classifies the 
overall quality of evidence as being either high, moderate, 
low or very low for each outcome of interest.32
Agreement
We calculated a kappa statistic to report agreement 
between reviewers for full-text inclusion.
Outcomes
For all outcomes, we compared early vasopressor use 
with standard resuscitation, which may or may not have 
included vasopressor therapy in patients unresponsive 
to intravenous fluid resuscitation. We prespecified the 
following outcomes of interest for the purpose of anal-
ysis: short-term mortality at longest follow-up up to 90 
days (primary outcome), long-term mortality beyond 90 
days, fluid and blood product requirements during the 
early resuscitation period, requirements for acute (up to 
90 days) or chronic (beyond 90 days) renal replacement 
therapy, duration of renal replacement therapy, dura-
tion of mechanical ventilation, incidence of acute kidney 
injury (as defined by individual study authors), incidence 
of vasopressor-associated adverse events (new-onset 
cardiac arrhythmia, digit, limb or skin ischaemia, mesen-
teric ischaemia and myocardial ischaemia), neurological 
outcome and long-term quality of life (no restriction on 
instruments used). Adverse events were documented as 
defined in individual studies.
summary measures and synthesis of results
We planned to include the results of clinically homoge-
neous studies in a random-effects quantitative meta-anal-
ysis. However, given the small number of included studies, 
their varying methodologies and their serious risk of bias, 
we judged quantitative meta-analysis to be inappropriate 
and instead report a qualitative summary of each study.33 
Data are presented as reported in individual studies. 
Additionally, dichotomous data are reported as risk ratios 
(RR) and continuous data as mean differences (MD), with 
associated 95% CI, in order to facilitate interpretation.
Additional analyses
We had also planned to conduct a number of subgroup 
analyses, which are detailed in the study protocol along 
with associated a priori hypotheses.26 The small number 
of studies and their variability in methods precluded 
subgroup analyses.
rEsults
study selection
Of 8001 citations, we retrieved 18 full-text articles and 
included 6 studies (1 RCT, 5 observational studies), 
including 2 studies published only in abstract form.34 35 
One highly cited observational study on vasopressor use 
in trauma was excluded because it addressed vasopressor 
use exclusively after patient arrival in the ICU.36 We iden-
tified two ongoing clinical trials (https:// clinicaltrials. 
gov/ show/ NCT01611935; https:// clinicaltrials. gov/ 
ct2/ show/ NCT00379522),37 38 but after contacting study 
personnel, the investigators preferred not to provide clin-
ical data for this review. A PRISMA flow chart illustrates 
the selection process (figure 1). Characteristics of eligible 
studies are detailed in table 1.
Outcomes
Short-term mortality
In the one eligible RCT, Cohn et al reported that survival 
to 30 days assessed by Kaplan-Meier curves was similar 
between patients receiving low-dose vasopressin infusions 
versus placebo (p=0.64).39
Across all observational studies, early vasopressor use 
was associated with a statistically significant (p<0.05) 
increased risk of short-term mortality (range of RR 2.31–
7.39; table 2). Sperry et al found this association to be 
significant despite adjusting for an extensive number of 
covariates (mortality: HR 1.81; 95% CI (1.1 to 2.9)).40 Van 
Haren et al performed a secondary analysis that excluded 
patients receiving epinephrine in order to eliminate 
patients with imminent cardiovascular collapse. Under 
such conditions, vasopressor use was not independently 
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associated with increased risk of death (p=0.52).41 Batis-
taki et al provided only the β coefficient associated with 
vasopressors in their logistic regression model, which 
leaves the direction of effect (−2.60) unclear, as it may 
refer to an association with either survival or mortality.42 
Although we attempted to contact study authors, we did 
not obtain a reply and were unable to clarify this issue 
(table 2).
Fluid and blood product requirements
Clinical trial data suggest that both fluid and blood 
product requirements were lower in patients treated 
early with vasopressin than in the control group (fluids: 
13.2±9.8 L vs 16.0±12.8 L, p=0.03; blood products: 
3.8±5.0 L vs 5.4±6.6 L, p=0.04). The MDs calculated from 
the data provided in the study do not yield statistically 
significant associations between these cointerventions 
and vasopressor use (fluids: MD −2.80 L, 95% CI (−7.83 to 
2.23); blood products: MD −1.60 L, 95% CI (−4.18 to 
0.98)). Study authors report a statistically significant 
association between vasopressin administration and fluid 
requirements at 120 hours, but not at the other prespeci-
fied time points (1 hour, 6 hours, 24 hours and 48 hours).39
In observational studies, fluid and blood product 
requirements were systematically higher among patients 
who received vasopressors34 35 40–42 (table 2).
Mechanical ventilation
Ventilator-free days were similar between groups (MD 2.2 
more days; 95% CI (−10.8 to 15.2)) in the clinical trial of 
early vasopressin administration versus placebo.
Meanwhile, in both observational studies that reported 
this intervention, mechanical ventilation requirements 
were higher for patients who received early vasopres-
sors35 40 (table 2).
Renal replacement therapy
Although not reported in the original publication, 
Hamada et al35 found no association between vaso-
pressor use and rates of renal replacement therapy (RR 
1.36, 95% CI (0.36 to 5.10); personal communication, S 
Hamada 2016) (table 2).
risk of bias within studies
The only RCT was blinded (patients and healthcare 
workers) but 12% of patients (9/78) were lost to 
follow-up at 30 days. This loss to follow-up could, under 
an extreme case scenario (all patients lost to follow-up 
in the intervention group survived while all those in the 
control group died), reverse the direction of effect.43 The 
study was terminated prematurely because of enrolment 
difficulties, which is a cause for concern where authors 
report potential benefits of vasopressors (fluid and blood 
Figure 1 PRISMA flow chart. ICU, intensive care unit; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-
Analyses.
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product requirements) since studies stopped early for 
benefit are at increased risk of bias.44 Moreover, fluid and 
blood product requirements were selectively reported at 
120 hours but not at the other prespecified time points. 
There were also more penetrating injuries (30% vs 16%) 
and gunshot wounds (26% vs 8%) in the control group 
than in the early vasopressin group, which introduces a 
potential baseline prognostic imbalance. We therefore 
graded this study as ‘very serious risk of bias’, although 
this is an uncommon decision when applying the GRADE 
methodology45 (table 3).
Significant baseline imbalances between patients 
treated with and without vasopressors suggest a high risk 
of selection bias for all included observational studies, 
where patients treated with vasopressors were system-
atically more severely injured. In one study,41 patients 
receiving vasopressors were less likely to have suffered 
a penetrating injury (59% vs 73%, p<0.001) but none-
theless had higher injury severity score (ISS) (25 vs 16, 
p<0.001). Three studies excluded patients who died of 
circulatory arrest on arrival34 35 or who did not survive 
48 hours postinjury,40 which introduces a significant 
risk of survivorship bias. One study excluded patients 
with TBI,35 although this population is more likely to 
receive vasopressors than non-brain-injured patients20 
(table 4).
Table 2 Effect of early vasopressor use in observational studies
Studies Vasopressor Control Effect estimate
Unadjusted short-term mortality (longest follow-up ≤90 days)
  Van Haren et al41 83/225 (37%) 26/521 (5%) RR 7.39 (4.90 to 11.16)
  Hamada et al35 17/39 (44%) 10/53 (19%) RR 2.31 (1.19 to 4.48)
  Batistaki et al42 11/22 (50%) 3/22 (14%) RR 3.67 (1.18 to 11.37)
  Sperry et al40 41/119 (34%) 71/802 (9%) RR 3.89 (2.79 to 5.43)
Adjusted short-term mortality (longest follow-up ≤90 days)
  Sperry et al40 HR 1.81 (1.1 to 2.9)*
Fluid received during early resuscitation period
  Van Haren et al41 (operative crystalloids, mL)† 4000 (3500) 3100 (3000) p<0.01
  Hamada et al35 (volume expansion, mL)† 1500 (1000) 1000 (750) p=0.01
  Gauss et al34 (prehospital fluid load, mL)† 1500 (1125) 1000 (940) p<0.01
Blood product given during early resuscitation period
PRBC use
  Van Haren et al41 (operative PRBC, mL)† 1250 (2938) 250 (1250) p<0.01
  Hamada et al35 (transfused PRBC, units)† 9.5 (7) 7 (6) p=0.05
  Gauss et al34 (units over first 24 hours)† 6.5 (6) 6 (3) p=ns
  Sperry et al40 (>6 units PRBC) 76/119 (64%) 71/802 (9%) RR 1.49 (1.28 to 1.75)
  Batistaki et al42 (total requirement, units)‡ 5.8 (1.9) 5.2 (1.5) p=0.2
FFP use
  Van Haren et al41 (operative FFP, mL)† 750 (1 750) 0 (750) p<0.01
  Sperry et al (mL)40 1704±1934 1001±1424 MD 703 (341 to 1064)
Renal replacement therapy use (≤90 days)
  Hamada et al35 4/39 (10%) 4/53 (8%) RR 1.36 (0.36 to 5.10)
Duration of mechanical ventilation (days)
  Hamada et al35 10.8±9.6 5.7±6.2 MD 5.1 (1.7 to 8.5)
  Sperry et al40 15.9±15 9.9±11 MD 6.0 (3.2 to 8.8)
All effect estimates are presented with associated 95% CIs.
Continuous data presented as mean±SD unless otherwise specified.
*Adjusted for age, gender, hospital centre, injury severity score (ISS), presenting Glasgow Coma Score, SBP <90 mm Hg on arrival, 
comorbidities (medical history of myocardial infarction, heart failure, chronic obstructive pulmonary disease (COPD), cirrhosis, smoking 
or alcoholism), blood product requirements, biochemical markers of injury (base deficit and pH), hyperglycaemia, requirement for major 
operative intervention, Acute Physiology and Chronic Health Evaluation (APACHE)  II score, use of a pulmonary artery catheter, steroid 
administration and aggressive crystalloid resuscitation (>16 L over 12 hours).
†Median (IQR).
‡Unclear if reported as mean or median.
FFP, fresh frozen plasma; MD, mean difference; ns, non-significant; PRBC, packed red blood cells; RR, relative risk; SBP, systolic blood 
pressure.
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synthesis of outcomes across studies
Table 5 presents a GRADE evidence profile summarising 
the overall quality of clinical trial evidence addressing 
vasopressor use following trauma. The overall quality of 
evidence is very low, due to the serious risk of bias and 
imprecision of effect estimates. We found no clinical trial 
data pertaining to a number of our prespecified clinical 
outcomes (long-term mortality, requirement for renal 
replacement therapy, adverse events (arrhythmia, digit, 
limb or skin ischaemia, mesenteric ischaemia, myocardial 
ischaemia and acute kidney injury), long-term neurolog-
ical function and long-term quality of life).
Agreement
We obtained a kappa statistic of 0.56 (95% CI 0.16 to 
0.97) for full-text inclusion.
DIsCussIOn
summary of evidence
This systematic review highlights that the balance between 
benefits and harms of vasopressor therapy during the 
early phase of resuscitation following traumatic injury is 
uncertain. The only RCT addressing the question is dras-
tically underpowered and also has risk of bias concerns. 
Table 3 Risk of bias in included randomised controlled trial
Cohn et al39 
Random sequence generation Low
Allocation concealment Unclear (high)
Blinding Low
Incomplete outcome data (mortality) High
Incomplete outcome data (other outcomes) Unclear (low)
Selective outcome reporting (mortality) Low
Selective outcome reporting (other outcomes) High
Other risks of bias High*†
Unclear (low): unclear but judged to be probably low risk of 
bias.
Unclear (high): unclear but judged to be probably high risk of 
bias.
*Trial stopped early.
 †Significant baseline imbalance between groups.
Table 4 Risk of bias in included observational studies
Batistaki
et al42
Sperry
et al40
Gauss 
et al34*
Hamada 
et al35*
Van Haren 
et al41
Selection of cohorts Unclear 
(high)
Low Low Low Low
Assessment of exposure Low Unclear 
(high)
Low Unclear 
(high)
Low
Absence of outcome at start of study (mortality) Low Low Low Low Low
Absence of outcome at start of study (other outcomes) Low Low Low Low Low
Matching or statistical adjustment (unadjusted mortality) High High High High High
Matching or statistical adjustment (adjusted mortality) High Unclear 
(high)
High N/A Unclear 
(high)
Matching or statistical adjustment (other outcomes) High High High High High
Assessment of prognostic factors Unclear 
(high)
Unclear 
(high)
Unclear 
(high)
Unclear 
(high)
Unclear 
(high)
Assessment of outcome (mortality) Low Low Low Unclear 
(high)
Low
Assessment of outcome (other outcomes) Low Low Low Unclear 
(high)
Low
Follow-up (mortality) Unclear 
(low)
Unclear 
(low)
Unclear 
(low)
Unclear 
(low)
Unclear 
(low)
Follow-up (other outcomes) Unclear 
(low)
Unclear 
(low)
Unclear 
(low)
Unclear 
(low)
Unclear 
(low)
Similarity of cointerventions Unclear 
(high)
High Unclear 
(high)
High High
Other risks of bias High† High†‡ High† High† High†
Unclear (low): unclear but judged to be probably low risk of bias.
Unclear (high): unclear but judged to be probably high risk of bias.
*We contacted the investigators of studies published exclusively as abstracts in order to perform risk of bias assessments.
†Important baseline imbalance between groups.
‡Survival bias (early deaths excluded).
N/A, not applicable.
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In the observational studies, vasopressor use was associ-
ated with worse outcomes. These results are at very high 
risk of bias because of prognostic imbalance and selection 
bias. The associations reported in these studies may be 
entirely attributable to confounding.
In light of the paucity of trustworthy evidence regarding 
the effects of vasopressor therapy in trauma, physicians 
charged with the care of patients with trauma face a clin-
ical conundrum: for a majority of patients, no therapy 
seems safe. Permissive hypotension, beneficial for patients 
who sustained penetrating torso injuries,6 is potentially 
harmful for patients who have suffered a TBI, in whom 
hypotension is associated with increased mortality.9 
The safety of this approach is also questionable outside 
densely populated urban centres where tertiary trauma 
care is rapidly available. In the landmark study by Bickell 
et al, the reported transport time was <15 min, which is not 
achievable in areas far from tertiary trauma centres.46 The 
alternative, fluid therapy, reportedly increases the risk of 
bleeding,6 coagulopathy,3 8 compartment syndrome47 and 
surgical complications.4 In this context, vasopressors are 
used in 6%–30% of patients with trauma in some centres, 
despite recommendations to limit their use.41 48 A recent 
survey of European trauma care providers concluded 
that vasopressor use was frequent, but controversial (76% 
respondents (171/225) agreed with vasopressor use).49 
This provides a strong rationale for clinical trials of vaso-
pressors during the early resuscitation phase of trauma 
victims.
Currently, the degree of uncertainty precludes any 
recommendation regarding vasopressor use in trauma 
(https://www. magicapp. org/ app#/ guideline/ 1273). 
Two clinical trials currently underway37 38 may provide 
useful insights on this question. However, they have not 
been designed a priori to capture long-term neurolog-
ical or quality of life-related outcomes. It is conceivable 
that interventions that decrease blood loss and improve 
short-term survival may worsen brain injury in vulner-
able subgroups, such as the elderly and victims of TBIs. 
Furthermore, the vasopressor choice of agent, as well 
as its dosing and timing of administration, has yet to be 
defined if this intervention is found to be beneficial.
strengths and limitations
The strengths of this review include the use of the GRADE 
approach to assess the overall quality of evidence. We 
performed a comprehensive review including non-pub-
lished literature. This review answers a clear question 
that focuses on a specific clinical scenario, which is 
the early phase of trauma care. In an effort to isolate 
the effects of vasopressors administered during active 
haemorrhage, we excluded studies that reported vaso-
pressor administration following a patient’s arrival to 
the ICU.
No standardised definition exists for what constitutes 
early trauma care, and others may define it differently 
and thus chose different eligibility criteria. The hetero-
geneous and sparse data limit our ability to draw firm 
conclusions; we were unable to pool estimates across 
study types and found very low certainty evidence.
COnClusIOns
This systematic review highlights the lack of reliable data 
on patient important outcomes to inform the use of 
vasopressors in the early phases of trauma resuscitation. 
Further rigorous randomised trials are needed to define 
the role of vasopressors in this clinical setting.
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